Related Experiment Video

Updated: Apr 28, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K

Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic

Wei Xin1, Zhiqin Lin, Shuhua Mi

  • 1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, China.

Heart Failure Reviews
|June 4, 2014
PubMed

Insights

BNP-guided therapy for chronic heart failure (CHF) significantly reduces heart failure hospitalizations. While not impacting overall mortality, this approach appears safe and promising for CHF patients, especially with substantial BNP reduction.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Clinical Trial Analysis

Background:

  • The clinical utility of B-type natriuretic peptide (BNP) in managing chronic heart failure (CHF) requires further clarification.
  • BNP levels are indicative of cardiac strain and can inform treatment decisions.

Purpose of the Study:

  • To conduct a meta-analysis evaluating the efficacy and safety of B-type natriuretic peptide (BNP)-guided therapy in patients with chronic heart failure (CHF).
  • To assess the impact of BNP-guided treatment on heart failure-related hospitalizations, all-cause mortality, and all-cause hospitalizations.

Main Methods:

  • Systematic literature search of PubMed, Embase, and Cochrane Library for relevant randomized controlled trials.
  • Meta-analysis using fixed or random effect models based on study heterogeneity.
  • Inclusion of 14 studies comprising 3,004 CHF patients.

Main Results:

  • BNP-guided therapy significantly reduced the risk of heart failure-related hospitalizations compared to clinical management (RR 0.79, p=0.03).
  • No significant effect was observed on all-cause mortality (RR 0.94, p=0.39) or all-cause hospitalizations (RR 0.97, p=0.56).
  • Substantial BNP reduction correlated with improved clinical outcomes; therapy demonstrated safety with no increased adverse events.

Conclusions:

  • BNP-guided therapy shows promise for improving clinical outcomes in CHF patients, particularly when significant BNP reduction is achieved.
  • The approach is deemed safe and warrants further investigation with optimized medication titration strategies.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

839

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
622
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.7K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
631
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
783